纳武利尤单抗治疗既往未治疗的BRAF野生型晚期黑色素瘤患者的生存结局:随机3期试验的3年随访
这项随机双盲3期CheckMate 066试验的3年随访分析显示,在既往未治疗的BRAF野生型晚期黑色素瘤患者中,纳武利尤单抗组3年总生存率为51.2%,达卡巴嗪组为21.6%;中位总生存期分别为37.5个月和11.2个月(HR 0.46,95%CI 0.36-0.59,P<.001)。
要点
- 纳武利尤单抗组3年总生存率为51.2%,达卡巴嗪组为21.6%。
- 纳武利尤单抗组中位总生存期37.5个月,达卡巴嗪组11.2个月(HR 0.46)。
- 纳武利尤单抗组完全缓解率19.0%,达卡巴嗪组1.4%。
核心结论
- 在既往未治疗的BRAF野生型晚期黑色素瘤患者中,与达卡巴嗪相比,纳武利尤单抗改善了3年总生存。
研究设计与样本
- 这是随机、对照、双盲3期CheckMate 066临床试验的3年总生存随访分析。
- 患者于2013年1月至2014年2月入组,为18岁及以上、确诊不可切除的既往未治疗III期或IV期黑色素瘤、ECOG体能状态0或1且无BRAF突变。
- 纳武利尤单抗组210例(中位年龄64岁,范围18-86岁;男性57.6%),达卡巴嗪组208例(中位年龄66岁,范围25-87岁;男性60.1%)。
- 纳武利尤单抗组至少随访38.4个月,达卡巴嗪组至少随访38.5个月。
主要发现
- 3年总生存率:纳武利尤单抗组51.2%(95%CI 44.1%-57.9%),达卡巴嗪组21.6%(95%CI 16.1%-27.6%)。
- 中位总生存期:纳武利尤单抗组37.5个月(95%CI 25.5个月-未达到),达卡巴嗪组11.2个月(95%CI 9.6-13.0个月);HR 0.46(95%CI 0.36-0.59;P<.001)。
- 完全缓解:纳武利尤单抗组19.0%(40/210),达卡巴嗪组1.4%(3/208)。
- 部分缓解:纳武利尤单抗组23.8%(50/210),达卡巴嗪组13.0%(27/208)。
- 治疗相关3/4级不良事件:纳武利尤单抗组15.0%(31/206),达卡巴嗪组17.6%(36/205);无研究药物毒性所致死亡。
临床怎么用
- 作者结论认为,在既往未治疗的BRAF野生型晚期黑色素瘤患者中,与达卡巴嗪相比,纳武利尤单抗改善了3年总生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: This analysis provides long-term follow-up in patients with BRAF wild-type advanced melanoma receiving first-line therapy based on anti-programmed cell death 1 receptor inhibitors. OBJECTIVE: To compare the 3-year survival with nivolumab vs that with dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma. DESIGN, SETTING, AND PARTICIPANTS: This follow-up of a randomized phase 3 trial analyzed 3-year overall survival data from the randomized, controlled, double-blind CheckMate 066 phase 3 clinical trial. For this ongoing, multicenter academic institution trial, patients were enrolled from January 2013 through February 2014. Eligible patients were 18 years or older with confirmed unresectable previously untreated stage III or IV melanoma and an Eastern Cooperative Oncology Group performance status of 0 or 1 but without a BRAF mutation. INTERVENTIONS: Patients were treated until progression or unacceptable toxic events with nivolumab (3 mg/kg every 2 weeks plus dacarbazine-matched placebo every 3 weeks) or dacarbazine (1000 mg/m2 every 3 weeks plus nivolumab-matched placebo every 2 weeks). MAIN OUTCOME AND MEASURE: Overall survival. RESULTS: At minimum follow-ups of 38.4 months among 210 participants in the nivolumab group (median age, 64 years [range, 18-86 years]; 57.6% male) and 38.5 months among 208 participants in the dacarbazine group (median age, 66 years [range, 25-87 years]; 60.1% male), 3-year overall survival rates were 51.2% (95% CI, 44.1%-57.9%) and 21.6% (95% CI, 16.1%-27.6%), respectively. The median overall survival was 37.5 months (95% CI, 25.5 months-not reached) in the nivolumab group and 11.2 months (95% CI, 9.6-13.0 months) in the dacarbazine group (hazard ratio, 0.46; 95% CI, 0.36-0.59; P < .001). Complete and partial responses, respectively, were reported for 19.0% (40 of 210) and 23.8% (50 of 210) of patients in the nivolumab group compared with 1.4% (3 of 208) and 13.0% (27 of 208) of patients in the dacarbazine group. Additional analyses were performed on outcomes with subsequent therapies. Treatment-related grade 3/4 adverse events occurred in 15.0% (31 of 206) of nivolumab-treated patients and in 17.6% (36 of 205) of dacarbazine-treated patients. There were no deaths due to study drug toxic effects. CONCLUSIONS AND RELEVANCE: Nivolumab led to improved 3-year overall survival vs dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01721772.
引用
- Ascierto PA, Long GV, Robert C, et al. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncol. 2019. PMID: 30422243. doi:10.1001/jamaoncol.2018.4514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。